Lawyer for Platinum Partners Founder Assails Prosecutors’ ‘Lies’ (Reuters)
NEW YORK (Reuters) – A lawyer for Mark Nordlicht, founder of defunct hedge fund firm Platinum Partners, assailed U.S. prosecutors at Nordlicht’s criminal trial on Wednesday, suggesting they deliberately misled jurors to boost their careers. “I’m going to show you lies told to you by the government,” Jose Baez told the jury during a fiery closing argument in Brooklyn federal court, where Nordlicht faces charges of defrauding investors.
Thursday 6/27 Insider Buying Report: ELOX, ADC (Nasdaq.com)
On Monday, Eloxx Pharmaceuticals (ELOX)’s Director, Ran Nussbaum, made a $1.8M purchase of ELOX, buying 200,000 shares at a cost of $9.00 a piece. So far Nussbaum is in the green, up about 5.6% on their buy based on today’s trading high of $9.51. Eloxx Pharmaceuticals is trading up about 4.5% on the day Thursday. And at Agree Realty Corp. (ADC), there was insider buying on Wednesday, by Director John Rakolta Jr. who bought 10,000 shares at a cost of $64.20 each, for a trade totaling $642,000. Before this latest buy, Rakolta Jr. purchased ADC on 4 other occasions during the past twelve months, for a total investment of $1.2M at an average of $58.60 per share. Agree Realty Corp. is trading up about 1.1% on the day Thursday.
The CEO & President of TG Therapeutics (NASDAQ: TGTX) is Buying Shares (Analyst Ratings)
Today, the CEO & President of TG Therapeutics (TGTX), Michael S. Weiss, bought shares of TGTX for $351.5K. The Company has a Price to Book ratio of 32.0979. Currently, TG Therapeutics has an average volume of 2,100. Starting in August 2018, TGTX received 30 Buy ratings in a row.
Ex-UBS Official, Friend Get 3 Years in Insider-Trading Case (2) (Bloomberg Law)
A former UBS Group AG compliance officer and her friend were sentenced to three years for insider trading after a London trial that featured accounts of champagne-fueled parties, burner phones and evidence stashed in a Chanel handbag. Ex-UBS employee Fabiana Abdel-Malek and day trader Walid Choucair were sentenced June 27 in London, with a judge saying that they will serve half the term in prison. After tearfully hugging her family, Abdel-Malek was taken into custody by guards. Choucair, wearing a…
A Director at Epizyme (NASDAQ: EPZM) is Selling Shares (Analyst Ratings)
Today, a Director at Epizyme (EPZM), David Mott, sold shares of EPZM for $1.37M. This is Mott’s first Sell trade following 5 Buy transactions. Following David Mott’s last EPZM Sell transaction on October 05, 2018, the stock climbed by 4.3%. Based on Epizyme’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $7.89 million and GAAP net loss of $29.34 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $34.07 million. Currently, Epizyme has an average volume of 1.11M.
